BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
2024年5月14日 - 8:30PM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the
“Company”), a commercial-stage biopharmaceutical company focused on
genetic diseases and cancers, today announced that members of its
management team will present at the Bank of America Merrill Lynch
Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday,
May 15 at 3:00 pm PT.
To access the live webcast of BridgeBio’s presentation, please
visit the “Events & Presentations” page within the Investors
section of the BridgeBio website
at http://investor.bridgebio.com. A replay of
the webcast will be available on the BridgeBio website for 90 days
following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage
biopharmaceutical company founded to discover, create, test, and
deliver transformative medicines to treat patients who suffer from
genetic diseases and cancers with clear genetic drivers.
BridgeBio’s pipeline of development programs ranges from early
science to advanced clinical trials. BridgeBio was founded in 2015
and its team of experienced drug discoverers, developers, and
innovators are committed to applying advances in genetic medicine
to help patients as quickly as possible. For more information
visit bridgebio.com and follow us
on LinkedIn and Twitter.
BridgeBio Contact:Vikram
Balicontact@bridgebio.com(650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
過去 株価チャート
から 4 2024 まで 5 2024
BridgeBio Pharma (NASDAQ:BBIO)
過去 株価チャート
から 5 2023 まで 5 2024